Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-03043-x
Abstract: Venetoclax treatment has demonstrated efficacy and a safety profile in chronic lymphocytic leukemia (CLL) patients, however the emergence of resistant cells is a current complication. We and others, previously reported that the activation of CLL… read more here.
Keywords: phenotype; resistant cll; cll; venetoclax ... See more keywords